Enzymatic oxidative deamination process

US6515170B1 · kind B1 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Ramesh N. Patel · Bound Brook, US
• Amit Banerjee · Yardley, US
• Venkata B. Nanduri · East Brunswick Township, US
• Steven L. Goldberg · Berkeley Heights, US
• Robert M. Johnston · Whitehouse Station, US
• Thomas P. Tully · Middlesex, US
• Laszlo J. Szarka · East Brunswick Township, US
• Shankar Swaminathan · Braunschweig, DE
• John J. Venit · New Brunswick, US
• Jerome L. Moniot · Richboro, US
• William J. Winter · Lebanon, US
• Neal G. Anderson · Stockton, US
• David A. Lust · Roosevelt, US
• Gerard Crispino · Princeton, US
• Sushil K. Srivastava

Key dates

• Filing date: Apr 26, 2001
• Grant date: Feb 4, 2003
• Expiry date: Jul 31, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention concerns an enzymatic oxidative deamination process of a dipeptide monomer to prepare an intermediate useful to prepare compounds having endopeptidase and angiotensin converting enzyme inhibition activity.